Literature DB >> 31655825

Plasma Homocysteine Level Is Associated with the Expanded Disability Status Scale in Neuromyelitis Optica Spectrum Disorder.

Jie Liang1, Jia Liu1, Rong Fan1, Zhigang Chen1,2, Xiaohong Chen1, Jiayi Tong3, Yong Chen3, Fuhua Peng1, Ying Jiang4.   

Abstract

BACKGROUND AND
OBJECTIVE: Plasma homocysteine (Hcy) levels have been investigated among patients with multiple sclerosis (MS). However, the changes in Hcy levels and the association between Hcy levels and inflammatory/immune/cerebrospinal fluid (CSF) parameters in neuromyelitis optica spectrum disorder (NMOSD) patients have not been investigated yet.
METHODS: Case data were collected from 97 acute-phase NMOSD patients and 39 stable-phase NMOSD patients. Patients in the acute phase were divided into 2 groups based on the EDSS score with cutoff equal to 4. Hcy levels, immunoglobulins (Ig) A, G, and M, complement 3 and 4, CH50, C-reactive protein, erythrocyte sedimentation rate (ESR), and CSF examination including white blood cells and total protein were determined.
RESULTS: No significant differences in Hcy levels are observed between acute-phase and stable-phase NMOSD patients. Hcy and ESR levels were significantly higher in acute-phase NMOSD patients with EDSS score ≥4. Besides, EDSS is positively correlated with Hcy level, ESR, 1/aquaporin-4 titer and Hcy level is negatively correlated with IgM in acute-phase NMOSD patients.
CONCLUSION: Elevated plasma Hcy has the potential to affect the pathogenesis or progression of NMOSD.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Complement; Expanded Disability Status Scale; Homocysteine; Neuromyelitis optica spectrum disorder

Year:  2019        PMID: 31655825     DOI: 10.1159/000503426

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  3 in total

1.  Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Haojie Xie; Yingzhe Shao; Juan Du; Yajun Song; Yanfei Li; Ranran Duan; Yaobing Yao; Zhe Gong; Junfang Teng; Yanjie Jia
Journal:  J Neurol       Date:  2021-08-12       Impact factor: 4.849

2.  Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease.

Authors:  Yaobing Yao; Xuan Yang; Yongyan Zhou; Haojie Xie; Ranran Duan; Lijun Jing; Yanfei Li; Wenjuan Guan; Junfang Teng; Yanjie Jia
Journal:  Front Neurol       Date:  2022-08-25       Impact factor: 4.086

3.  Sarcoidosis and neuromyelitis optica in a patient with optic neuritis - a case report.

Authors:  Michael A Foster; Sara Collorone; Jacqueline Palace; James Acheson; Ahmed T Toosy
Journal:  Ann Clin Transl Neurol       Date:  2021-06-24       Impact factor: 5.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.